Permanent gastric electrical stimulation in children and adolescents
Study ID: STU 082014-034
The FDa approved indication for enterra HDe is for gastric electrical stimulation is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Patients will be offered therapy if they meet the following criteria 1) patients with delayed gastric emptying based on a nuclear medicine gastric emptying study 2) refractory or intolerant to prokinetic and anti-emetic therapy
To be able to provide permanent gastric electical stimulation as a treatment option to pediatric patients with drug-refractory nausea and vomiting associated with gastroparesis of diabetic or idiopathic origin.